计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
GW274150 是一种选择性和高效性的 NADPH 依赖型人一氧化氮合成酶 (iNOS) (Kd=40 nM) 和大鼠诱导型一氧化氮合酶 (iNOS) 双重抑制剂。GW274150 对人和大鼠的内皮一氧化氮合酶 (eNOS) 和神经元一氧化氮合酶 (nNOS) 活性较低。在急性肺损伤炎症模型中,GW274150 表现出保护作用
GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) ( IC 50 =2.19 μM; K d =40 nM) and rat iNOS ( ED 50 =1.15 μM). GW274150 also displays less potency for both humans or rats endothelial NOS ( eNOS ) and neuronal NOS ( nNOS ). GW274150 exerts a protective role in an acute model of lung injury inflammation
In Vitro
GW274150 inhibits intracellular iNOS in J774 cells in a time-dependent manner, reaching IC 50 values of 0.2 μM. GW274150 is >260-fold and 219-fold selective for iNOS against eNOS and nNOS in rat tissues, respectively. And it displays >100-fold and >80-fold for human iNOS against human eNOS and nNOS, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
GW274150 is a long-acting (5 h half‐life in rats) iNOS inhibitor and is able to inhibit LPS‐mediated increase in plasma NO2 - , NO3 - levels 14 h after single intraperitoneal dose (ED 50 =3 mg/kg). GW274150 (intraperitoneal injection; 2.5, 5, and 10 mg/kg; before carrageenan injection) reduces the degree of lung injury induced by carrageenan in a dose-related fashion. Oedema formation and PMNs infiltration in the pleural cavity are also significantly attenuated in a dose‐related manner in rats. GW274150 (oral adminstration; 30 mg/kg; twice daily; 7 days) leads to significant neuroprotection, However, it displays a bell-shaped neuroprotective profile, being ineffective at high doses in 6-OHDA rat model of Parkinson disease (PD). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SD-ratDosage: 2.5, 5 and 10 mg/kg; single dose Administration: Intraperitoneal injection 5 min before carrageenan injection Result: Exerted a protective role in an acute model of inflammation, carrageenan-induced lung injury.
IC50& Target:Kd: 40 nM (iNOS), IC50: 2.19 μM (human iNOS),544 μM (human eNOS),177 μM (human nNOS) ED50: 1.15 μM (rat iNOS),252 μM (rat nNOS)
| ALogP | -3.3 |
|---|